Literature DB >> 31705444

Sarcopenia and fatty liver disease.

Jung A Kim1, Kyung Mook Choi2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease which may progress to non-alcoholic steatohepatitis. The prevalence of sarcopenia, which is the loss of muscle mass and strength, is increasing in the aging society. Recent studies reported the relationship between NAFLD and sarcopenia. The skeletal muscle is the primary organ for glucose disposal. Loss of muscle mass can cause insulin resistance, which is an important risk factor for NAFLD. Moreover, obesity, chronic low-grade inflammation, vitamin D deficiency, physical inactivity, hepatokines, and myokines might be involved in the pathophysiologic mechanism of sarcopenia and NAFLD. Although most of the previous studies have demonstrated the positive correlation between sarcopenia and NAFLD, the difference in diagnostic methods of sarcopenia and NAFLD leads to difficulties in interpretation and application. This review discusses the concept and diagnosis of sarcopenia and NAFLD, common pathophysiology, and clinical studies linking sarcopenia to NAFLD. The presentation of the association between sarcopenia and NAFLD may provide an opportunity to prevent the deterioration of fatty liver disease.

Entities:  

Keywords:  Liver; Non-alcoholic fatty liver disease; Pathophysiology; Sarcopenia; Skeletal muscle

Mesh:

Year:  2019        PMID: 31705444     DOI: 10.1007/s12072-019-09996-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  98 in total

1.  Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.

Authors:  Ho Cheol Hong; Soon Young Hwang; Hae Yoon Choi; Hye Jin Yoo; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  Hepatology       Date:  2014-03-24       Impact factor: 17.425

2.  Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people.

Authors:  D Baylis; D B Bartlett; H E Syddall; G Ntani; C R Gale; C Cooper; J M Lord; A A Sayer
Journal:  Age (Dordr)       Date:  2012-03-03

3.  Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans.

Authors:  Hae Yoon Choi; Sungeun Kim; Ji Woo Park; Nam Seok Lee; Soon Young Hwang; Joo Young Huh; Ho Cheol Hong; Hye Jin Yoo; Sei Hyun Baik; Byung-Soo Youn; Christos S Mantzoros; Kyung Mook Choi
Journal:  J Clin Endocrinol Metab       Date:  2014-04-29       Impact factor: 5.958

4.  Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability.

Authors:  Ian Janssen; Steven B Heymsfield; Robert Ross
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

5.  Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease.

Authors:  Kerry-Lee Milner; David van der Poorten; Aimin Xu; Elisabetta Bugianesi; James G Kench; Karen S L Lam; Donald J Chisholm; Jacob George
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 6.  A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach.

Authors:  Helen C Roberts; Hayley J Denison; Helen J Martin; Harnish P Patel; Holly Syddall; Cyrus Cooper; Avan Aihie Sayer
Journal:  Age Ageing       Date:  2011-05-30       Impact factor: 10.668

Review 7.  Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis.

Authors:  Michal Steffl; Richard W Bohannon; Lenka Sontakova; James J Tufano; Kate Shiells; Iva Holmerova
Journal:  Clin Interv Aging       Date:  2017-05-17       Impact factor: 4.458

8.  Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis.

Authors:  Hye Jin Yoo; Soon Young Hwang; Ju-Hee Choi; Hyun Jung Lee; Hye Soo Chung; Ji-A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

Review 9.  The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Ji-Young Cha; Da-Hyun Kim; Kyung-Hee Chun
Journal:  Lab Anim Res       Date:  2018-12-31

10.  Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.

Authors:  Andras Franko; Dietrich Merkel; Marketa Kovarova; Miriam Hoene; Benjamin A Jaghutriz; Martin Heni; Alfred Königsrainer; Cyrus Papan; Stefan Lehr; Hans-Ulrich Häring; Andreas Peter
Journal:  Nutrients       Date:  2018-09-17       Impact factor: 5.717

View more
  17 in total

Review 1.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

2.  Impedance-based measures of muscle mass can be used to predict severity of hepatic steatosis in pediatric nonalcoholic fatty liver disease.

Authors:  Toshifumi Yodoshi; Sarah Orkin; Emily Romantic; Kathryn Hitchcock; Ana-Catalina Arce Clachar; Kristin Bramlage; Qin Sun; Lin Fei; Andrew T Trout; Stavra A Xanthakos; Marialena Mouzaki
Journal:  Nutrition       Date:  2021-08-10       Impact factor: 4.893

Review 3.  Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease.

Authors:  Jelena Stevanović; Jorge Beleza; Pedro Coxito; António Ascensão; José Magalhães
Journal:  Mol Metab       Date:  2019-11-29       Impact factor: 7.422

4.  Association of the triglyceride and glucose index with low muscle mass: KNHANES 2008-2011.

Authors:  Jung A Kim; Soon Young Hwang; Ji Hee Yu; Eun Roh; So-Hyeon Hong; You-Bin Lee; Nam Hoon Kim; Hye Jin Yoo; Ji A Seo; Nan Hee Kim; Sin Gon Kim; Sei Hyun Baik; Kyung Mook Choi
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

5.  Psoas muscle area and paraspinal muscle fat in children and young adults with or without obesity and fatty liver.

Authors:  Salman S Albakheet; Mi-Jung Lee; Haesung Yoon; Hyun Joo Shin; Hong Koh
Journal:  PLoS One       Date:  2021-11-17       Impact factor: 3.240

6.  Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction.

Authors:  Mingwei Guo; Liping Xiang; Jing Yao; Jun Zhang; Shuangshuang Zhu; Dongmei Wang; Caizhi Liu; Guoqiang Li; Jiawen Wang; Yuqing Gao; Cen Xie; Xinran Ma; Lingyan Xu; Jian Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-21       Impact factor: 5.555

7.  Excessive alcohol intake and liver fibrosis are associated with skeletal muscle mass reduction in elderly men: the Wakayama study.

Authors:  Shuhei Onishi; Nobuyuki Miyai; Yan Zhang; Toshifumi Oka; Eriko Nogami; Miyoko Utsumi; Mikio Arita
Journal:  Aging Clin Exp Res       Date:  2021-06-12       Impact factor: 3.636

8.  High Salt Diet Impacts the Risk of Sarcopenia Associated with Reduction of Skeletal Muscle Performance in the Japanese Population.

Authors:  Yasuko Yoshida; Keisei Kosaki; Takehito Sugasawa; Masahiro Matsui; Masaki Yoshioka; Kai Aoki; Tomoaki Kuji; Risuke Mizuno; Makoto Kuro-O; Kunihiro Yamagata; Seiji Maeda; Kazuhiro Takekoshi
Journal:  Nutrients       Date:  2020-11-12       Impact factor: 5.717

Review 9.  Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?

Authors:  Ivana Mikolasevic; Tajana Pavic; Tajana Filipec Kanizaj; Darija Vranesic Bender; Viktor Domislovic; Zeljko Krznaric
Journal:  Can J Gastroenterol Hepatol       Date:  2020-10-31

Review 10.  Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.

Authors:  Vittoria Zambon Azevedo; Cristina Alina Silaghi; Thomas Maurel; Horatiu Silaghi; Vlad Ratziu; Raluca Pais
Journal:  Front Nutr       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.